Sonnet Biotherapeutics receives shareholder approval for business merger with Hyperliquid Strategies Inc.
ChainCatcher News, according to market sources, Nasdaq-listed biotechnology company Sonnet Biotherapeutics has received shareholder approval and plans to merge its business with Hyperliquid Strategies Inc.
Previously, it was reported that Hyperliquid Strategies submitted an S-1 filing, aiming to raise up to 1 billion USD, which may be used to purchase HYPE tokens.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
PRECIOUS-Gold lacklustre as higher-for-longer rate outlook weighs on sentiment
Novo Nordisk is open to upgrading its New York listing status.
Novo Nordisk considers upgrading its New York listing to boost its U.S. profile
Crypto prices
More
